AbbVie Agrees to Buy Apogee Therapeutics for $10.9 Billion, Betting on a Less-Frequent Rival to Dupixent

AbbVie's Biggest Bet Since Allergan

AbbVie CEO Robert A. Michael announced today that the company has signed a definitive agreement to acquire Apogee Therapeutics, a clinical-stage biotech with a pipeline focused on inflammatory and immunological diseases. The all-cash deal values Apogee at $10.9 billion, making it AbbVie's largest acquisition in more than five years, according to CNBC.

Apogee shareholders would receive $135.11 per share. That's a 49.49% premium to where the stock closed last Thursday, according to CNBC. Apogee shares were up roughly 47% in premarket trading this morning; AbbVie shares were up about 1.5%.

Both companies' boards unanimously approved the deal, according to the joint press release published today by Apogee Therapeutics' investor relations.

The Drug That Makes This Worth $10.9 Billion

The centerpiece of the acquisition is zumilokibart (APG777), a subcutaneous monoclonal antibody that inhibits IL-13, a protein involved in allergic inflammation. It is being studied for moderate-to-severe atopic dermatitis — the chronic skin condition commonly called eczema — and asthma.

What separates zumilokibart from existing treatments is dosing frequency. Sanofi and Regeneron's Dupixent, the current market leader in atopic dermatitis, requires an injection every two weeks. Zumilokibart is being studied as a shot given once every three to six months. If that clinical profile holds up, it offers a meaningful patient convenience advantage.

RBC Capital Markets analyst Brian Abrahams told CNBC the deal aligns with AbbVie's strengths and called AbbVie "an ideal acquirer to maximize zumilokibart's potential," citing the drug's reduced dosing burden and the size of the atopic dermatitis market.

Apogee's pipeline also includes APG273, a combination of zumilokibart and APG333, an anti-TSLP antibody, being developed for asthma. AbbVie's press release describes the combined pipeline as having "mega-blockbuster peak sales potential."

Why AbbVie Needs This

AbbVie's immunology franchise generated more than $30 billion in revenue in 2025, up 14% year-over-year, according to CNBC. The growth was driven by Skyrizi and Rinvoq as Humira — once the world's best-selling drug — continued its post-patent collapse, with sales falling 49% last year.

The Humira cliff was always coming. AbbVie has spent years filling the hole. The $10.1 billion purchase of ImmunoGen, which brought in the ovarian cancer drug Elahere, and the Cerevel Therapeutics deal for neurological and psychiatric disease candidates were part of the same strategy, according to CNBC. Apogee is the immunology chapter.

Apogee CEO Michael Henderson said the transaction "delivers substantial shareholder value and positions our programs to reach their full potential," according to the joint press release. AbbVie's Michael framed it as an extension of the company's more than two decades of immunology leadership.

Separately, Pharmaceutical Executive reported that AbbVie has also been investing in U.S. manufacturing capacity: a $175 million device manufacturing facility acquired from West Pharmaceutical Services in Tempe, Arizona in January, and a $380 million expansion of active pharmaceutical ingredient manufacturing in North Chicago announced in February. Those moves are part of a stated commitment to invest over $10 billion in U.S. capital over the next decade. The Apogee deal is a different animal — pipeline, not plants.

The Case for Skepticism

The strongest objection to this deal is clinical: zumilokibart has not yet cleared Phase 3 trials. AbbVie is paying nearly $11 billion for a drug that is still in development, against a competitor in Dupixent that already holds a dominant market position and deep physician familiarity. If the clinical data on once-every-three-months dosing doesn't survive a pivotal trial, or if the safety profile introduces complications, the strategic premise evaporates. That's a real risk. Paying a 49% premium on top of it is a genuine bet, not a certainty.

AbbVie has absorbed clinical-stage acquisitions before and has the infrastructure to run large trials efficiently. But pharma graveyards are full of compounds that looked like Dupixent-beaters and weren't.

Financials and Closing Timeline

AbbVie said the transaction is expected to be accretive to adjusted earnings per share beginning in 2032, according to CNBC. That's a six-year runway before it adds to the bottom line on an adjusted basis, a timeline that reflects both the cost of the deal and the time needed to push zumilokibart through remaining trials, regulatory review, and commercial launch.

Closing is expected in the third quarter of 2026, subject to Apogee shareholder approval and regulatory clearance, according to the Apogee investor relations press release.

The unresolved question hanging over the deal is Phase 3. AbbVie has not disclosed when it expects pivotal trial data for zumilokibart in atopic dermatitis. That readout, whenever it comes, will determine whether $10.9 billion was disciplined portfolio-building or an expensive bet that didn't pay.